Get the Stockscreener App
5.00
5.84%
-0.31
After Hours:
5.00
Alvotech stock is traded at $5.00, with a volume of 1.06M.
It is down -5.84% in the last 24 hours and down -1.96% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$5.31
Open:
$5.27
24h Volume:
1.06M
Relative Volume:
0.91
Market Cap:
$1.78B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
51.87
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
-13.49%
1M Performance:
-1.96%
6M Performance:
+38.12%
1Y Performance:
-42.86%
1-Day Range:
$4.95
$5.30
1-Week Range:
$4.95
$5.89
52-Week Range:
$2.94
$9.00
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.00 | 1.78B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-26 | Upgrade | Barclays | Underweight → Overweight |
| Aug-24-26 | Initiated | BofA Securities | Buy |
| Aug-14-26 | Initiated | Evercore ISI | Outperform |
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech (ALVO) Shares Climb 6.96% to $6.15 as Buyers Reclaim GroundHedge Fund Exposure - siam.in
Certain Ordinary Shares of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026. - marketscreener.com
What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media
Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - MarketBeat
Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP
Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat
FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net
Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance
Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance
Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st
Bank of America sees major upside in this biotech stock - Yahoo Finance
Alvotech to present at upcoming investor conferences in September - Yahoo Finance
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - Sahm
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo
Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - Pulse 2.0
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT) - The Globe and Mail
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets - Yahoo Finance UK
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang
Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha
Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat
Alvotech Q2 Earnings Call Highlights - MarketBeat
Alvotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
2.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):